Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease. Am J Hematol 2009 Apr;84(4):231-3
Date
03/18/2009Pubmed ID
19291727DOI
10.1002/ajh.21370Scopus ID
2-s2.0-64549155231 (requires institutional sign-in at Scopus site) 24 CitationsAbstract
Baseline level of the cysteinyl leukotriene (CysLT), leukotriene E4 (LTE4), is associated with an increased pain rate in children and adults with sickle cell disease (SCD). To provide additional evidence for a role of CysLTs in the pathogenesis of vaso-occlusion, we tested the hypothesis that LTE4 levels will increase within an individual during painful episodes compared to baseline. In a cohort of 19 children and adults with SCD, median LTE4 levels increased from 82.36 pg/mg creatinine at baseline to 162.81 pg/mg creatinine during a painful episode (P < 0.001). These data further support a contribution of CysLTs to the process of vaso-occlusion.
Author List
Field JJ, Strunk RC, Knight-Perry JE, Blinder MA, Townsend RR, DeBaun MRAuthor
Joshua J. Field MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AcetatesAdolescent
Adult
Anemia, Sickle Cell
Anti-Asthmatic Agents
Asthma
Biomarkers
Child
Cohort Studies
Cyclopropanes
Female
Fetal Hemoglobin
Hemoglobin C Disease
Heterozygote
Hospitalization
Humans
Ischemia
Leukotriene Antagonists
Leukotriene E4
Male
Pain
Quinolines
Retrospective Studies
Sickle Cell Trait
Sulfides
Young Adult
beta-Thalassemia
